Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Cymbalta keeps growing in pain states

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA approval of Lilly's Cymbalta (duloxetine) for management of fibromyalgia June 16 comes on the heels of a May sNDA submission for management of chronic pain that is backed by the same trial data that supported the fibromyalgia filing. Lilly also submitted chronic pain data from three additional trials, two in chronic low back pain and one in osteoarthritis of the knee. OA of the knee data from a 231-patient trial that Lilly characterized as "the first time duloxetine has been studied in a large, placebo-controlled trial in … an inflammatory disease state" was presented to the European League Against Rheumatism annual congress in Paris June 13. On the primary efficacy measure of mean 24-hour pain score, 59 percent of duloxetine OA of the knee patients reported a 30 percent improvement in pain compared with 45 percent of placebo patients; a 50 percent improvement in pain was reported by 47 percent of duloxetine and 29 percent of placebo patients. The serotonin and norepinephrine reuptake inhibitor's expansion from its core antidepressant use was inaugurated by a diabetic neuropathic pain claim approved Sept. 3, 2004

You may also be interested in...



Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions

Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.

Cara Placing Korsuva Hopes On Oral Formulation, Broad Pruritis Label

I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.

‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines

China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel